Washington (AFP) | 19/06/2026 - 22:58:50 | Washington slams Cuba reforms as 'superficial'
London (AFP) | 19/06/2026 - 22:40:24 | One dead, several injured in UK train collision: police
Washington (AFP) | 19/06/2026 - 21:23:07 | Qatar-gifted Air Force One replacement unveiled
Caracas (AFP) | 19/06/2026 - 20:58:10 | Venezuelan opposition leader heads to US after transition talks
Jerusalem (AFP) | 19/06/2026 - 20:52:09 | Israel 'committed' to Lebanon ceasefire if Hezbollah honours it: Israel ambassador to US
Kyiv (AFP) | 19/06/2026 - 20:37:22 | Kyiv says Poland stripping Zelensky of award is 'strategic mistake' and 'disrespectful'
Warsaw (AFP) | 19/06/2026 - 20:27:35 | Poland's president says stripping Zelensky of top award
London (AFP) | 19/06/2026 - 19:55:57 | Two trains reported to have collided north of London: transport police
Beirut (AFP) | 19/06/2026 - 19:34:30 | Lebanon's Aoun tells Rubio 'comprehensive ceasefire' essential: presidency
San José (AFP) | 19/06/2026 - 18:40:29 | Costa Rican president evacuated after blast heard near illegal mining zone
Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/David Weinreich, Global Head of R&D and Chief Medical Officer “People living with lupus continue to fa...
Starting date: September 1, 2025
Deadline for applications: July 25, 2025
Location: Berlin, Germany - Europe region
THE JOB
AFP is seeking a dynamic and motivated native-level English-speaking correspondent to join its reporting team in Berlin, Germany.
